• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1133
  • N225
  • 38780.14
  • 1.3 %
  • 496.2891
  • FTSE
  • 8289.43
  • 0.33 %
  • 27.35
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.25
Biofrontera Inc. (BFRIW) Stock Price, News & Analysis

Biofrontera Inc. (BFRIW) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.06

-$0

(-1.69%)

Day's range
$0.06
Day's range
$0.06
50-day range
$0.015
Day's range
$0.23
  • Country: US
  • ISIN: US09077D1182
52 wk range
$0.06
Day's range
$0.06
  • CEO: Dr. Hermann Luebbert Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -8.02
  • Piotroski Score 2.00
  • Grade N/A
  • Symbol (BFRIW)
  • Company Biofrontera Inc.
  • Price $0.06
  • Changes Percentage (-1.69%)
  • Change -$0
  • Day Low $0.06
  • Day High $0.06
  • Year High $0.06

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/30/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.30
  • Trailing P/E Ratio -0.05
  • Forward P/E Ratio -0.05
  • P/E Growth -0.05
  • Net Income $-20,131,000

Income Statement

Quarterly

Annual

Latest News of BFRIW

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Biofrontera Inc. Frequently Asked Questions

  • What is the Biofrontera Inc. stock price today?

    Today's price of Biofrontera Inc. is $0.06 — it has decreased by -1.69% in the past 24 hours. Watch Biofrontera Inc. stock price performance more closely on the chart.

  • Does Biofrontera Inc. release reports?

    Yes, you can track Biofrontera Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Biofrontera Inc. stock forecast?

    Watch the Biofrontera Inc. chart and read a more detailed Biofrontera Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Biofrontera Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Biofrontera Inc. stock ticker.

  • How to buy Biofrontera Inc. stocks?

    Like other stocks, BFRIW shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Biofrontera Inc.'s EBITDA?

    Biofrontera Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Biofrontera Inc.’s financial statements.

  • What is the Biofrontera Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.5908543923, which equates to approximately -59.09%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Biofrontera Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Biofrontera Inc.'s financials relevant news, and technical analysis. Biofrontera Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Biofrontera Inc. stock currently indicates a “sell” signal. For more insights, review Biofrontera Inc.’s technical analysis.

  • A revenue figure for Biofrontera Inc. for its last quarter?

    Biofrontera Inc. published it's last quarterly revenues at $9.01 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.